ClinicalTrials.gg
CompletedNCT02482753Updated Jan 12, 2022

Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer

A Phase 3 interventional study of Chidamide and exemestane in Breast Cancer, sponsored by Chipscreen Biosciences, Ltd.. Completed at 22 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-12.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
365
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing tucidinostat in Breast Neoplasms — 6 open to participants now, 6 under way, none of them phase 3. tucidinostat · Breast Neoplasms.

Enrollment
Largest of 21
365 · median 44
Started
2015
with 1 other
Phase 3
Only one
of the 21
Registered
1st of 21
by date
Lead sponsor
1 of 21
Chipscreen Biosciences, Ltd.

Among the 21 studies testing tucidinostat in Breast Neoplasms, this one has the largest enrollment, is one of 2 that started in 2015, is the only one in phase 3, and was the 1st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 21 studies testing tucidinostat in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

About tucidinostat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing tucidinostat in Breast Neoplasms, or all of them as a file.
02

Study summary

This study was to evaluate the efficacy and safety of Chidamide in combination with exemestane in postmenopausal patients with hormone-receptor positive advanced breast cancer.

Read the detailed description

This study including two parts: (1) Part A, open-label design, 20 patients will be enrolled and receive 30 mg Chidamide BIW and 25 mg exemestane QD. The main object of part A is to evaluate the pharmacokinetic and pharmacodynamic profile of Chidamide when in combination with exemestane. (2) Part B, randomized and double-blinded design, 328 patients will be assigned randomly in a 2:1 ratio to experiment group (30 mg Chidamide BIW + 25 mg exemestane QD) and control group (placebo BIW + 25 mg exemestane QD), to evaluate the efficacy and safety of Chidamide when in combination with exemestane in patients with locally advanced or metastatic estrogen receptor-positive breast cancer progressing on endocrine therapy.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Chidamide
  • breast cancer
  • exemestane
  • Estrogen Receptor
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 \~ 75 years old, women;
  2. Histological or cytological confirmation of hormone receptor-positive [estrogen receptor (ER) positive and progesterone receptors (PgR) positive or negative] breast cancer;
  3. Disease progression or recurrence after at least one endocrine therapy (either in advanced/ setting or setting);
  4. ≤4 prior therapies (either in advanced/metastatic setting or adjuvant setting), patients may have received one prior chemotherapy;
  5. The disease condition is inoperable, stage III or stage IV, at least one or simple bone metastases with no measurable lesions;
  6. Last prior therapy intervals: (a) if the last treatment was endocrine therapy, the interval must ≥ 2 weeks; (b) if the last treatment was chemotherapy therapy, the interval must ≥ 4 weeks;
  7. Performance Status: 0\~1;
  8. ≥ 1.5×109 / L, count ≥ 100×109 / L, ≥ 90 g/L;
  9. ≥ 3 months;
  10. Have signed .

Exclusion criteria

Exclusion Criteria:

  1. Patients have known central nervous system (CNS) or a history of , or with ;
  2. Patients with human epidermal growth factor receptor-2 (Her-2) positive;
  3. Patients previously received treatment with exemestane;
  4. Patients received radiotherapy ≤ 4 weeks prior to study entry;
  5. Patients with no (except simple bone metastasis), such as pleural or pericardial effusion, ascites, et al;
  6. Patients have uncontrolled or significant cardiovascular disease, including:

    1. Myocardial infarction (\< the last 12 months)
    2. Uncontrolled angina (\< the last 6 months)
    3. Congestive heart failure (\< the last 6 months), or (LVEF) \< 50% prior to study entry
    4. History of any significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or TdP)
    5. History of significant prolongation, or Corrected QT Interval (QTc) > 450 ms prior to study entry
    6. History of cerebrovascular accident
    7. Symptomatic coronary heart disease requiring treatment with agents
  7. The size of fluid area detected by cardiac ultrasonography in cavum pericardium is ≥10mm during diastolic period;
  8. History of organ transplantation;
  9. Patients have not recovered from all toxicities to grade 1 due to prior therapies;
  10. Patients have clinical significant gastrointestinal abnormality, e.g., unable to swallow, chronic diarrhea, ileus, that would interfere the ingestion,transportation or absorption of oral agents;
  11. Active infection [Suffered from active infection of bacteria, virus, fungi, mycobacteria, parasites, or other infections (excluding nail bed fungal infections), or require intravenous antibiotic therapy, or antiviral therapy, or hospitalization due to any significant infection events], or persistent fever within 14 days prior to study entry;
  12. Patients had organ surgery \< 6 weeks prior to study entry;
  13. Abnormal liver function [total > 1.5× (> 3×upper limit of normal in case of Gilbert syndrome); Transaminases (, AST) >2.5×upper limit of normal (>5x upper limit of normal patients with liver metastases), abnormal renal function (serum creatinine > 1.5×upper limit of normal);
  14. Patients with prior invasive with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ, unless received curative treatment and with documented evidence of no recurrence in the past five years;
  15. Any mental or cognitive disorder, that would interfere the ability to understand the document or the operation and compliance of study;
  16. Patients are currently enrolled in another drug study, or completed within 4 weeks prior to study entry, with the exception of patients only in overall survival follow-up;
  17. Any other condition which is inappropriate for the study in the opinion of the investigators.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
365 participants (actual)

Study arms

  • Experimental
    Chidamide + exemestane, open-label

    Patients receive 30 mg Chidamide per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

    Drug: Chidamide · Drug: exemestane

  • Experimental
    Chidamide + exemestane, double-blinded

    Patients receive 30 mg Chidamide twice per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

    Drug: Chidamide · Drug: exemestane

  • Placebo comparator
    placebo + exemestane, double-blinded

    Patients receive placebo twice per week and 25 mg exemestane PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

    Drug: exemestane · Drug: placebo

Interventions

  • 30 mg, administered orally twice per week (BIW)

    Also known as: CS055

  • 25 mg, PO daily

    Also known as: Aromasin

  • Drugplacebo

    Administered orally twice per week (BIW)

    Also known as: Simulation tablet of Chidamide

06

What researchers measure

Primary outcomes

  1. progression-free survival (PFS), double-blinded period

    PFS is measured from the date of randomization until progression or death, whichever is first met

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years

  2. pharmacokinetic profiles of Chidamide, open-label period

    The pharmacokinetic parameters include Area under the plasma concentration versus time curve (AUC) , Peak Plasma Concentration (Cmax), time to reach Cmax (Tmax), mean concentration at steady state (Css)

    Time frame: 0,1,2,4,8,12,24,48,72 hours after the first dose of Chidamide on day 2 at induced stage (4 days in total); 0,1,2,4,8,12,24,48,72 hours post-dose on day 1 of cycle 1 at combination treatment stage

  3. pharmacokinetic profiles of exemestane, open-label period

    The pharmacokinetic parameters include Area under the plasma concentration versus time curve (AUC) , Peak Plasma Concentration (Cmax), time to reach Cmax (Tmax), mean concentration at steady state (Css)

    Time frame: 0,1,2,4,8,12,24 hours after the first dose of exemestane on day 1 at induced stage (4 days in total); 0,1,2,4,8,12,24,48,72 hours post-dose on day 1 of cycle 1 at combination treatment stage

  4. acetylation level of histone H3, open-label period

    The acetylation level of histone H3 is assayed by enzyme-linked immuno sorbent assay (ELISA).

    Time frame: pre-dose of Chidamide on day 2 at induced stage (4 days in total); pre-dose of Chidamide on day 1 of cycle 2 at combination treatment stage

Secondary outcomes

  1. overall survival, double-blinded period

    OS is measured from the date of randomization until death

    Time frame: Time from randomization to death from any cause, assessed up to 6 years

  2. duration of response (DOR), double-blinded period

    DOR is measured from the first date when criteria for response is met until the first date when the criteria for progression is met

    Time frame: From the first date of response until the date of first documented progression, assessed up to 3years

  3. objective response rate (ORR), open-label period and double-blinded period

    ORR is defined as percentage of participants with Complete Response and Partial Response, assessed by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST)

    Time frame: Response is assessed once every 6 weeks, assessed up to 3 years

  4. clinical benefit rate (CBR), open-label period and double-blinded period

    ORR is defined as percentage of participants with Complete Response, Partial Response or Stable Disease ≥ 24 weeks, assessed by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST)

    Time frame: Response is assessed once every 6 weeks, assessed up to 3 years

  5. PFS, open-label period

    PFS is measured from the start of treatment until progression or death, whichever is first met

    Time frame: Time from the start of treatment to the earliest of documented disease progression, or death, assessed up to 3 years

07

Study locations

22 sites
  • Anhui Provincial Hospital
    Hefei, Anhui 230001, China
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230022, China
  • The 307th Hospital of Chinese people's Liberation Army
    Beijing, Beijing 100021, China
  • Beijing Cancer Hospital
    Beijing, Beijing 100036, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
  • Cangzhou Central Hospital
    Cangzhou, Hebei 061001, China
  • Tumor Hospital of Hebei Province
    Shijiazhuang, Hebei 050019, China
  • Harbin Medical University Cancer Hospital
    Ha'erbin, Heilongjiang 150081, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
  • Hunan Cancer Hospital
    Changsha, Hunan, China
  • Zhejiang Cancer Hospital
    Hangzhou, Jiangsu 310022, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu 210009, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • The Third Hospital of Nanchang
    Nanchang, Jiangxi 330009, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130012, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning 110042, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200032, China
  • Fudan University ZhongShan Hospital
    Shanghai, Shanghai 200032, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
08

References and documents

Publications

  • Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C, Tong Z, Cheng Y, Pan Y, Sun Y, Wang H, Ouyang T, Gu K, Feng J, Wang X, Wang S, Liu T, Gao J, Cristofanilli M, Ning Z, Lu X. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Jun;20(6):806-815. doi: 10.1016/S1470-2045(19)30164-0. Epub 2019 Apr 27. PubMed 31036468 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Mar 2018, 32 months.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 32 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2015
First posted
Jun 26, 2015
StartActual
Jul 2015
Primary completionActual
Mar 2018
CompletionActual
Feb 2021
Last update
Jan 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02482753
Responsible party
Sponsor
First posted
Jun 26, 2015
Start date
Jul 2015
Primary completion
Mar 2018
Completion
Feb 2021
Last update
Jan 12, 2022

Study contacts

Zefei Jiang
principal investigator · 307 Hospital of PLA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucidinostat

Start the discussion